Strategic acquisitions and product expansions could catalyze further upward movement. Now, I'll spend the next few minutes discussing our results at the product category level. Our Digestive Health portfolio continues to deliver excellent results with over 9% organic growth versus prior year. This performance was bolstered by our NeoMed product line which posted another terrific quarter, growing double digits versus the prior year, as we continue to take advantage of the strong demand for ENFit conversions in North America. While we are currently experiencing solid double-digit growth, we anticipate slower growth over the next few quarters as we enter the late stages of the ENFit adoption. Our legacy ENFit feeding business also posted a strong quarter, growing mid-single digits compared to the previous year. As noted during our last call, we anticipate mid to high single-digit growth organically for our Digestive Health portfolio this year and our ability to deliver above-market growth will be supported by innovations we plan to launch during the back half of the year, expansion into additional global markets with attractive growth prospects, low-growth product rationalization and actionable M&A opportunities. On the profitability front, despite a 5% increase in operating expenses to $6.2 million , net losses decreased by 10% to $3.0 million . This $0.4 million improvement in bottom-line performance signals progress in cost management, particularly from reduced interest expenses and the elimination of underperforming assets like the Hawaii clinic. Several hedge funds have increased holdings, adding conviction to the ivp stock price forecast for the second half of